Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Of taxes and tariffs; the dealing begins; yelling at Yellin; Paul Singer not amused by Bloomberg report; and more!

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...

Detailed price information for Avid Bioservices Inc (CDMO-Q) from The Globe and Mail including charting and trades.

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.